Birzeit Pharmaceuticals Company (PEX: BPC)
Palestine
· Delayed Price · Currency is JOD · Price in USD3.750
0.00 (0.00%)
At close: Oct 3, 2024
BPC Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 39.51 | 43.13 | 47.03 | 45.47 | 35.85 | 34.58 | Upgrade
|
| Revenue Growth (YoY) | -12.29% | -8.31% | 3.44% | 26.82% | 3.70% | -2.73% | Upgrade
|
| Cost of Revenue | 26.66 | 28.16 | 30.13 | 28.14 | 22.42 | 19.75 | Upgrade
|
| Gross Profit | 12.85 | 14.97 | 16.91 | 17.33 | 13.43 | 14.83 | Upgrade
|
| Selling, General & Admin | 6.08 | 6.94 | 7.13 | 6.84 | 6.28 | 6.07 | Upgrade
|
| Operating Expenses | 6.93 | 7.79 | 7.35 | 7.01 | 6.55 | 7 | Upgrade
|
| Operating Income | 5.92 | 7.18 | 9.56 | 10.31 | 6.88 | 7.83 | Upgrade
|
| Interest Expense | -0.03 | -0.09 | -0.11 | -0.2 | -0.24 | -0.13 | Upgrade
|
| Interest & Investment Income | - | - | - | - | - | 0 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.66 | -0.34 | -1.91 | 0.05 | 0.23 | 0.38 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.23 | 0.26 | 0.12 | 0.09 | 0.07 | 0.06 | Upgrade
|
| EBT Excluding Unusual Items | 5.46 | 7 | 7.67 | 10.26 | 6.94 | 8.14 | Upgrade
|
| Gain (Loss) on Sale of Investments | -2.04 | -0.06 | 2.05 | 2.69 | 1.33 | 0.15 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.05 | - | 0.16 | - | 0.3 | Upgrade
|
| Asset Writedown | - | - | -0.69 | 0.27 | - | 1.7 | Upgrade
|
| Other Unusual Items | - | - | - | - | -0.12 | - | Upgrade
|
| Pretax Income | 3.42 | 7 | 9.02 | 13.38 | 8.15 | 10.29 | Upgrade
|
| Income Tax Expense | 0.69 | 0.85 | 1.09 | 1.21 | 0.78 | 0.74 | Upgrade
|
| Earnings From Continuing Operations | 2.73 | 6.15 | 7.93 | 12.17 | 7.38 | 9.55 | Upgrade
|
| Minority Interest in Earnings | -0.03 | -0.04 | 0.01 | -0.09 | -0.01 | -0.03 | Upgrade
|
| Net Income | 2.7 | 6.12 | 7.95 | 12.08 | 7.37 | 9.52 | Upgrade
|
| Net Income to Common | 2.7 | 6.12 | 7.95 | 12.08 | 7.37 | 9.52 | Upgrade
|
| Net Income Growth | -55.82% | -23.05% | -34.21% | 63.91% | -22.63% | 20.51% | Upgrade
|
| Shares Outstanding (Basic) | 38 | 38 | 38 | 39 | 39 | 39 | Upgrade
|
| Shares Outstanding (Diluted) | 38 | 38 | 38 | 39 | 39 | 39 | Upgrade
|
| Shares Change (YoY) | 1.00% | 1.00% | -2.38% | - | - | - | Upgrade
|
| EPS (Basic) | 0.07 | 0.16 | 0.21 | 0.31 | 0.19 | 0.25 | Upgrade
|
| EPS (Diluted) | 0.07 | 0.16 | 0.21 | 0.31 | 0.19 | 0.25 | Upgrade
|
| EPS Growth | -56.26% | -23.81% | -32.60% | 63.92% | -22.63% | 20.51% | Upgrade
|
| Free Cash Flow | 4.7 | 8.83 | 1.62 | 2.72 | 5.13 | 6.84 | Upgrade
|
| Free Cash Flow Per Share | 0.12 | 0.23 | 0.04 | 0.07 | 0.13 | 0.18 | Upgrade
|
| Dividend Per Share | - | - | 0.100 | 0.050 | 0.073 | 0.108 | Upgrade
|
| Dividend Growth | - | - | 100.00% | -31.97% | -31.82% | 46.67% | Upgrade
|
| Gross Margin | 32.52% | 34.71% | 35.94% | 38.11% | 37.46% | 42.88% | Upgrade
|
| Operating Margin | 14.99% | 16.65% | 20.32% | 22.68% | 19.19% | 22.64% | Upgrade
|
| Profit Margin | 6.84% | 14.18% | 16.90% | 26.56% | 20.55% | 27.55% | Upgrade
|
| Free Cash Flow Margin | 11.90% | 20.47% | 3.44% | 5.98% | 14.30% | 19.79% | Upgrade
|
| EBITDA | 7.33 | 8.68 | 11.22 | 11.98 | 8.57 | 9.44 | Upgrade
|
| EBITDA Margin | 18.54% | 20.12% | 23.85% | 26.34% | 23.89% | 27.29% | Upgrade
|
| D&A For EBITDA | 1.4 | 1.5 | 1.66 | 1.66 | 1.69 | 1.61 | Upgrade
|
| EBIT | 5.92 | 7.18 | 9.56 | 10.31 | 6.88 | 7.83 | Upgrade
|
| EBIT Margin | 14.99% | 16.65% | 20.32% | 22.68% | 19.19% | 22.64% | Upgrade
|
| Effective Tax Rate | 20.12% | 12.09% | 12.07% | 9.05% | 9.51% | 7.21% | Upgrade
|
| Advertising Expenses | - | - | - | 0.11 | 0.07 | 1.14 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.